Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

Abstract: The present invention provides a method for measuring a surface plasmon resonance, the method enabling easy detection of the existence of a phosphorylated peptide (protein) and determination whether a peptide is phosphorylated or not in biological materials. The present invention also provides a noble metal compound having high capability of coordination to a phosphorylated peptide, and being conveniently usable in the method. A first method for measuring surface plasmon resonance of the present invention comprises: placing a noble metal compound on a bottom face of a prism, irradiating a light to the prism to detect a reflected light, wherein, the noble metal compound has substituents of following formula (I) on a side opposite to a side contacting the prism, and a subject sample is added to a side having the substituent groups (I) in the noble metal compound.

Abstract: The present invention provides a method for measuring a surface plasmon resonance, the method enabling easy detection of the existence of a phosphorylated peptide (protein) and determination whether a peptide is phosphorylated or not in biological materials. The present invention also provides a noble metal compound having high capability of coordination to a phosphorylated peptide, and being conveniently usable in the method. A first method for measuring surface plasmon resonance of the present invention comprises: placing a noble metal compound on a bottom face of a prism, irradiating a light to the prism to detect a reflected light, wherein, the noble metal compound has substituents of following formula (I) on a side opposite to a side contacting the prism, and a subject sample is added to a side having the substituent groups (I) in the noble metal compound.

Abstract: It is an objective of the present invention to provide a positron tomography method applicable to the diagnosis of specific brain diseases and to provide a positron-emitting compound for use in the method. The present invention method relates to a positron tomography method for measuring a distribution and concentration of a positron-emitting source, and is characterized in using the compound (I) as the positron-emitting source.

Abstract: Provided are a method for easily detecting phosphorylated peptides, namely, proteins, in samples derived from living organisms or the like, a method for selectively adsorbing the phosphorylated peptides, and compounds that are highly coordinated to the phosphorylated peptides and usable in the methods. The complex compound is represented by the formula: wherein X is a linker moiety, and Y is a labeling group. The compound (I) is highly coordinated to a phosphorylated peptide, and has a labeling group. Accordingly, with use of the compound (I), the phosphorylated peptide can be easily identified.

Abstract: Provided are a method for easily detecting phosphorylated peptides, namely, proteins, in samples derived from living organisms or the like, a method for selectively adsorbing the phosphorylated peptides, and compounds that are highly coordinated to the phosphorylated peptides and usable in the methods.